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1 Introduction
Premature delivery is the single most important
obstetrical complication associated with perinatal
mortality and morbidity. An additional one or two
weeks of intrauterine existence may decrease
neonatal morbidity and mortality. The physiologic
aspects of the onset of labor remain an enigma to
modern medicine. The exact cause and mechanism
of the inhibition of human parturition are unknown
and many theories have been advanced to explain
the onset of labor: oxytocin, alpha catecholamins,
progesterone drop, estrogen-progesteron ratio
elevation, fetal corticosteroids, prostaglandins,
changes in uterine blood flow and uterine disten-
sion. These factors may also be responsible for
premature labor.
The problem of how to inhibit labor is not a new
one. Traditionally patients have been treated by
bed rest, sedation and avoidance of vaginal exami-
nations. Many drugs have also been used including
progestogens [9], ethyl alcohol [7], beta adrenergic
drugs [16], magnesium sulphate [26] and diazoxide
[15]. The marked cardiovascular side effects of the
beta adrenergic receptor stimulants may limit their
use in the treatment of preterm labor [3]. A role
for prostaglandins in spontaneous labor is sug-
gested by their presence in the amniotic fluid
[10] in the blood of humans at the onset of labor
[32] and by the observation that exogenously
administed prostaglandins can induce labor [11,
12] or abortion [13, 21]. There is also good evi-
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dence that prostaglandins play an important role
in the pathogenesis of premature labor [14].
Prostaglandins synthetase inhibitors are known
relaxants of the gravid uterus. The nonsteroid anti-
inflammatory agents such as aspirin, indomethacin,
salicylic acid, naproxen, meclofenamic acid are
potent inhibitors of prostaglandin biosynthesis in
the body. The purpose of this study was to test
the efficacy and safety of indomethacin in sup-
pressing the premature labor and expands a
previously reported study [30]. In the first part of
the study prospective uncontrolled large group of
patients treated with indomethacin for premature
labor were evaluated for efficacy and safety and in
second part (see the following article) a double
blind study was conducted.
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2 Materials and methods
A trial of indomethacin was conducted in 297
women in premature labor. The patients were aged
between 16 and 44 years. There were 120 primi-
paras and 177 multiparas. The gestational age at
admission varied between 24 and 34 completed
weeks of pregnancy. There were 45 patients with
premature rupture of membranes. Patients were
admitted to the trial if regular, painful contrac-
tions were occurring at frequency of two or more
in 10 minutes. In all patients uterine activity was
recorded with external cardiotocography during
a control period of at least 30 minutes to obtain a
baseline of activity before indomethacin was
administered. Patients with suspected intra-uterine
growth retardation, toxemia, uterine malforma-
tions, fever, vaginal bleeding, oligohydramnios and
polyhydramnios were excluded. Every patient
received 100mg of indomethacin (rectally) in
suppository form followed by 25 mg (orally) every
6 hours until the contractions had been inhibited
for 24 hours. If uterine contractions continued
after the initial rectal dose of indomethacin the
patient received an additional 100 mg suppository
after 1 hour and then the treatment was continued
orally. The total daily dose needed for successful
treatment was between 200 and 300 mg of indo-
methacin and the patient was under hospital obser-
vation during 1 to 2 days. No other drugs were
used and all patients gave informed consent to the
study. Treatment was considered to have been
successful when the premature contractions were
arrested completely for more than 1 week. Where
uterine activity ceased for between 48 hours and
7 days, treatment was considered to be of moder-
ate value. The treatment was considered ineffec-
tive if contractions could not be stopped or if they
commenced again and delivery took place within
48 hours of the start of therapy. Maternal pulse
and blood pressure, uterine contractions and fetal
heart rate were monitored during treatment. The
criterion for prematurity was a birth age of less
than 37 weeks gestation confirmed at delivery by
the criteria described by DUBOWITZ et al. [6].
3 Results
The effect of indomethacin treatment on prema-
ture labor was evaluated by cessation of uterine
contractions and the period of prolongation of
gestation. Thirty minutes after indomethacin
administration uterine contractions decreased in
frequency and intensity and complete uterine
relaxation was noted within 2—13 hours. Tab. I
shows the results of indomethacin treatment.
After indomethacin treatment premature labor
stopped completely for 1 to 12 weeks in 83% of
patients. In 10% the treatment was of moderate
value, i.e. the uterine contractions were stopped
for 2 to 7 days. The 7 % of the patients in which
the treatment was ineffective were delivered in 48
hours. Indomethacin was less effective in cases in
which the cervix was dilated more than 4 cm
whereas uterine contractions were arrested com-
pletely in 90% of the cases where the cervical
dilatation was 3 cm or less. When the dilation was
more than 3 cm the contractions were stopped in
only 58% of the cases. Premature labor also more
Tab. I. Results of indomethacin treatment for premature labor in relation to status of membranes and cervical dilation.
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readily suppressed in women with intact mem-
branes (88 %) compared with those with ruptured
membranes (53%). In most cases the delay in
delivery ranged from 5—9 weeks although in 49
patients delivery was delayed as much as 11—12
weeks (Tab. II). In 48 patients it was necessary to
repeat the treatment as contractions reappeared
after 2 week interval.
Fifty-one premature babies were born in spite of
therapy and 15 of these (5 % of the all group) died
from respiratory distress syndrome (weights of
700—1500 g). The remaining 36 premature infants
and the 246 mature infants were in good condition
at birth and were all examined by a pediatrician.
Meconium was noted in the amniotic fluid in
18 cases (6%) and no ill effects relating to the
treatment were observed. The development of
these children who were seen at follow-up exami-
nation during a period of up to 5 years of age, was
satisfactory.
Where labor was not supressed the course of labor
and delivery was completely normal with no
increased need for obstetrical interference. Indo-
methacin therapy did not alter maternal blood
pressure or pulse rate or fetal heart rate. Minor
side effects were seen however including nausea,
vomiting and dyspepsia (8 patients), maculopapular
eruption (2 patients) and epistaxis (1 patient). All
symptoms disappeared within a few hours of
discontinuing therapy.











































The intruduction of indomethacin as an inhibitor
of labor resulted from animal and human studies
which indicated that prostaglandins play an impor-
tant role in parturition. Inhibition of production
and release of prostaglandin by administration of
aspirin or indomethacin has been shown to be
associated with inhibition of labor and prolonged
parturition in the rat [1] and delay of midtrimester
abortion induced by hypertonic saline in the
human [27]. It is also known that patients taking
salicylates chronically during pregnancy have a
higher incidence of gestation beyond 42 weeks [5],
and indomethacin has been shown to delay the
onset of parturition in pregnant rhesus monkeys
[19]. Indomethacin was shown to have an inhibi-
tory effect on prostaglandin synthesis or release
and decrease of plasma level of PGF2a after 30—
60 minutes of its administration [31].
Our study of 297 women shows that indomethacin
completely inhibited premature labor in 83 % of
the patients. A moderate effect was achieved in
10% of patients and this delay of premature labor
for 2 to 7 days allowed the administration of
betamethasone in an attempt to improve fetal lung
maturity. The inhibitory effect of indomethacin
on uterine contractions and the subsequent delay
of delivery, decreased with the progress of cervical
dilatation and with the presence of ruptured mem-
branes. These results compare favorably with other
reported series using oral indomethacin alone
[4,29] or oral therapy following unsuccessful
administration of beta-sympathomimetic agents
[8]. The total dose administered was usually higher
and the duration of administration was usually
longer in these series however.
The main theoretical problem associated with the
administration of indomethacin is the possibility
of this agent causing premature closure of the
ductus arteriosus. Case reports claiming to demon-
strate a correlation between the ingestion of
prostaglandin antagonists and congenital ductus
closure [2], and primary neonatal pulmonary
hypertension [17] are not well substantiated and
do not take into account the thousands of women
suffering from rheumatoid arthritis who are
exposed to large doses of these drugs during preg-
nancy without any apparent deleterious effect on
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the fetal circulation. SHAPIRO et al. [22] reported
that among 40,000 pregnant women (25,000 were
treated with aspirin and 15,000 were a control
group) no change in perinatal mortality was seen.
A variation in the sensitivity of the ductus
arteriosus to indomethacin at different gestations
in the rat has been clearly demonstrated by
SHARPE et al. [23, 24]. Maximal sensitivity to this
drug was found only when it was adminstered
12—18 hours prior to delivery at term, whereas
administration at 18 days of age (premature) had
no effect at all.
The lack of deleterious effect on the cardio-
vascular system in our group of infants may have
been due to the fact the indomethacin was not
given when the gestation exceeded 35 weeks, and
similar reasons could explain the lack of complica-
tions reported by other workers using indo-
methacin to inhibit premature labor [4, 8, 18, 25,
29]. It is of interest, however, that even when
indomethacin was administered within 24 hours of
delivery at term [20] no fetal cardiovascular com-
plications occurred. Because of the virtual com-
plete absence of maternal side effects, patient
acceptance of the therapy is much higher than
when treatment with beta-adrenergic drugs has
been proposed.
Summary
Prematurity still remains one of the unsolved problems in
obstetrics and is responsible for a majority of cases of
perinatal morbidity and mortality. The use of indo-
methacin to stop uterine contractions and prevent prema-
ture delivery is based on the observation that indo-
methacin inhibits the release of prostaglandin which is
assumed to play a role in the induction and continuation
of labor. The effect of indomethacin as an antagonist to
prostaglandin was evaluated in a series of 297 women in
premature labor. The gestational age at admission varied
between 24 and 34 weeks of pregnancy (120 primiparas
and 177 multiparas). In 83 % of cases there was complete
cessation of labor for a period of 1 to 12 weeks, in 10 %
of cases from 2 to 7 days and in 7 % there was no effect.
The delay of premature labor for 2 to 7 days allowed the
administration of betamethasone in an attempt to
improve fetal lung maturity. The total daily dose needed
for successful treatment was between 200-300 mg indo-
methacin. Dilation of cervix beyond 4 cm was associated
with successful treatment in 58% compared to 90% if
cervix was dilated 3 cm or less. In comparing women with
intact membranes to women with ruptured, the success
rate in suppressing premature labor was significant; 88%
versus 53%. In 49 patients delivery was delayed 11-12
weeks.
Fifty-one babies were born in spite of therapy, and of
these 15 with birth weights of 700-1500 g suffered from
respiratory distress syndrome and died. All the rest
(36 premature and 246 mature infants) showed no ill
effects related to the treatment. During a 5 years follow-
up period of these children, normal development was seen
in all cases. No intoward effects were observed on mater-
nal or fetal wellbeing during and after treatment. Minor
side effects such as nausea, vomiting and dyspepsia
occured in 8 patients, a maculopapular eruption occured
in 2 patients and epistaxis in 1 patient. These side effects
disappeared a few hours after stopping the medication.
The results suggest that indomethacin is an effective and
well tolerated inhibitor of premature labor.
Keywords: Indomethacin, premature labor, prostaglandin synthetase inhibitor, uterine contractions.
Zusammenfassung
Weitere Untersuchungen zur Hemmung vorzeitiger Wehen
durch Indometacin - Teil I
Frühgeburten gehören zu den ungelösten Problemen in
der Geburtshilfe; sie verursachen die Mehrzahl der Fälle
von perinataler Morbidität und Mortalität. Der Einsatz
von Indometacin zur Wehenhemmung und Verhinderung
vorzeitiger Geburt basiert auf der Beobachtung, daß
Indometacin die Freisetzung von Prostaglandinen, die
scheinbar für die Geburtseinleitung und ihren Ablauf von
Bedeutung sind, hemmt. Der in Bezug auf die Prostaglan-
dine antagonistische Effekt des Indometacins wurde bei
297 Frauen mit drohender Frühgeburt untersucht. Das
Gestationsalter bei Aufnahme lag zwischen der 24. und
34. Schwangerschaftswoche (120 Erstgebärende und
177 Mehrgebärende). Bei 83% der Fälle wurden die
Wehen über einen Zeitraum von l bis zu 12 Wochen
gehemmt, bei 10 % von 2 bis 7 Tagen und bei 7 % wurde
kein Effekt erzielt. Die Verzögerung der Geburt um 2 bis
7 Tage ermöglichte die Gabe von Betamethason zur
Induktion der Lungenreifung. Für eine suffiziente
Behandlung mußte täglich eine Gesamtdosis von 200-
300 mg Indometacin verabreicht werden. War der Mutter-
mund mehr als 4 cm geöffnet, so war die Therapie in 58 %
der Fälle erfolgreich, während bei einer Muttermunds-
öffnung von 3 cm und weniger ein Behandlungserfolg bei
90 % erreicht werden konnte. Vergleicht man die Ergeb-
nisse bei Frauen mit und ohne Blasensprung, so war der
Unterschied signifikant: 53% versus 88%. Bei 49 Patien-
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tinnen konnte die Geburt um 11 bis 12 Wochen hinausge-
zögert werden.
In 51 Fällen kam es trotz der Therapie zur Geburt;
15 Neugeborene mit einem Geburtsgewicht zwischen
700 und 1500g hatten ein RDS und verstarben. Die
übrigen Kinder (36 Frühgeborene und 246 reife Neuge-
borene) zeigten keine Symptome, die mit der Therapie in
Zusammenhang gebracht werden konnten. Die Kinder
wurden über einen Zeitraum von 5 Jahren beobachtet; in
allen Fällen sahen wir eine normale Entwicklung.
Während und nach der Therapie schien der mütterliche
und fetale Zustand nicht beeinträchtigt. Bei 8 Patien-
tinnen wurden Nebenwirkungen wie Übelkeit, Erbrechen
und Durchfall beobachtet, bei 2 Patientinnen trat ein
makulo-papulöses Exanthem auf und l Patientin hatte
eine Epistaxis. Diese Nebenwirkungen verschwanden
wenige Stunden nach Absetzen der Medikation. Die
Ergebnisse zeigen, daß Indometacin ein effektiver und gut
verträglicher Hemmstoff vorzeitiger Wehen ist.
Schlüsselwörter: Indometacin, Prostaglandinsynthetase-Hemmstoff, Uteruskontraktionen, vorzeitige Wehen.
Resume
Etude complementaire du blocage de l'accouchement
premature par rindometacine - I
La prematurite demeure encore un des problemes non
resolus en obstetrique et est responsable de la majeure
partie des cas de morbidite et de mortalite perinatales.
L'utilisation de rindometacine pour arreter les contrac-
tions uterines et eviter Taccouchement premature est
fondee sur Fobservation de Finhibition que ce
medicament entraine, de la liberation des prostaglandines
supposees, joue un röle dans l'induction et la poursuite de
l'accouchement. L'effet antagoniste des prostaglandines
de rindometacine a ete etudie sur une serie de 297
femmes en travail prematurement. L'äge gestationnel ä
l'admission etait compris entre 24 et 34 semaines de
grossesse (120 promipares et 177 multipares). Dans
83% des cas, il y eut un arret complet du travail pour
une duree de l ä 12 semaines, dans 10% des cas pour une
duree de 2 ä 7 jours et dans 7 % des cas il n'y eut aucun
effet. Le delai de 2 ä 7 jours avant Taccouchement rend
possible Tadministration de Betamethasone afin
d'ameliorer la maturite pulmonaire fetale. La dose
quotidienne necessaire pour un traitement efficace est
comprise entre 200 et 300 mg d'indometacine. A partir de
4 cm de dilatation cervicale le traitement a ete efficace
dans 58% des cas alors qu'il a ete efficace dans 90% des
Mots-cles: Accouchement premature, contractions uterines, indometacine, inhibiteur de la synthese des
pro staglandines.
Bibliography see part II.
cas lorsque la dilatation etait inferieure ou egale ä 3 cm.
Si compare les patientes avec membranes intactes et
les patientes avec une rupture, le pourcentage de succes
de prevention de Faccouchement premature est
significativement different: 88% contre 53%. Chez
49 patientes le delai avant Taccouchement a ete de 11 ä
12 semaines.
55 enfants sont nes malgre le traitement, et parmi eux,
15 avec un poids de naissance compris entre 700 et 1500g
ont presente un syndrome de detresse respiratoire et sont
morts. Tous les autres (36 prematures et 246 enfants ä
terme) ne prosenterent pas d'effets secondaires nefastes en
rapport avec le traitement. Un developpement normal a
ete observe dans tous les cas avec un recul de 5 ans de
surveillance de ces enfants. On a observe aucun effet
secondaire sur le bien-etre fetal ou maternel pendant et
apres le traitement. Des effets minimes secondaires tels
que nausees, vomissements et dyspepsie sont survenus
chez 8 patientes, une eruption maculo-papulaire a ete vue
chez 2 patientes et un epistaxis chez l patiente. Ces effets
secondaires ont disparu quelques heures apres Tarret du
traitement. Ces resultats suggerent que rindometacine
represente un inhibiteur efficace et bien tolere de
Taccouchement premature.
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